Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28928798 | 0.76 | CYP17A1 (0.44) | CYP17A1CYP11B1CYP11B2TBXAS1NFKB1 | |
| SCHEMBL12115795 | 0.76 | CYP17A1 (0.44) | CYP17A1CYP11B1CYP11B2TBXAS1NFKB1 | |
| SCHEMBL4338960 | 0.76 | TBXAS1 (0.49) | CYP17A1CYP11B1CYP11B2TBXAS1NFKB1 | |
| SCHEMBL4066404 | 0.75 | — | — | |
| SCHEMBL10654788 | 0.75 | — | — | |
| SCHEMBL11448112 | 0.74 | CYP17A1 (0.42) | CYP17A1CYP11B1CYP11B2TBXAS1NFKB1 | |
| SCHEMBL28023186 | 0.74 | CYP17A1 (0.42) | CYP17A1CYP11B1CYP11B2TBXAS1NFKB1 | |
| Bromide SCHEMBL28286964 | 0.74 | TBXAS1 (0.47) | CYP17A1CYP11B1CYP11B2TBXAS1NFKB1 | |
| Iodide SCHEMBL27677678 | 0.74 | TBXAS1 (0.47) | CYP17A1CYP11B1CYP11B2TBXAS1NFKB1 | |
| Hydrochloric Acid SCHEMBL28328253 | 0.74 | TBXAS1 (0.50) | CYP17A1CYP11B1CYP11B2TBXAS1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3524663-A1 | IMIDAZOLE CONTAINING QUATERNARY AMMONIUM SALTS | The Lubrizol Corporation (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20170114297-A1 | IMIDAZOLE CONTAINING QUATERNARY AMMONIUM SALTS | THE LUBRIZOL CORPORATION | 2017-04-27 | — | — | US | disclosed |
| CN-106574198-A | Imidazole containing quaternary ammonium salts | 路博润公司 | 2017-04-19 | — | — | CN | disclosed |
| US-20110230481-A2 | DERIVATIVES OF TETRABROMOBENZIMIDAZOLE, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, A METHOD OF USING THE SAME, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES, AND SERINE/THREONINE KINASES MODULATING AGENT | SELVITA S.A. (PL) | 2011-09-22 | — | — | US | disclosed |
| EP-2366695-A1 | A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent | SELVITA S.A. (PL) | 2011-09-21 | — | — | EP | disclosed |
| EP-2193204-B1 | COMPOSITIONS COMPRISING LIPOPHOSPHORAMIDES AND THEIR USES IN GENE THERAPY | UNIV BRETAGNE OCCIDENTALE (FR) | 2011-08-31 | — | — | EP | disclosed |
| US-20110112091-A1 | DERIVATIVES OF TETRABROMOBENZIMIDAZOLE, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, A METHOF OF USING THE SAME, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES, AND SERINE/THREONINE KINASES MODULATING AGENT | SELVITA SP. Z O.O. (PL) | 2011-05-12 | — | — | US | disclosed |
| EP-2193204-A2 | NOVEL LIPOPHILIC COMPOSITIONS AND USES THEREOF | Universite de Bretagne Occidentale (FR) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009050372-A2 | NOVEL LIPOPHILIC COMPOSITIONS AND USES THEREOF | UNIVERSITE DE BRETAGNE OCCIDENTALE (FR) | 2009-04-23 | — | — | WO | disclosed |
| EP-1378230-B1 | Para-phenylenediamine derivatives comprising a pyrrolidinyl group substituted by a cyclic radical and their use in colouring keratinic fibres | OREAL (FR) | 2007-11-14 | — | — | EP | disclosed |
| EP-1378230-A1 | Para-phenylenediamine derivatives comprising a pyrrolidinyl group substituted by a cyclic radical and their use in colouring keratinic fibres | L'OREAL (FR) | 2004-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112091-A1 | DERIVATIVES OF TETRABROMOBENZIMIDAZOLE, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, A METHOF OF USING THE SAME, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES, AND SERINE/THREONINE KINASES MODULATING AGENT | PIM1, PIM2, PIM3 | CYP17A1 2960/4885CYP11B1 1971/4885CYP11B2 2367/4885 |
| US-20110230481-A2 | DERIVATIVES OF TETRABROMOBENZIMIDAZOLE, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, A METHOD OF USING THE SAME, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES, AND SERINE/THREONINE KINASES MODULATING AGENT | PIM1, PIM2, PIM3 | CYP17A1 2266/4885CYP11B1 1658/4885CYP11B2 1786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.